Cryptosporidiosis – Pipeline Review, H2 2017

Global Markets Direct’s, ‘Cryptosporidiosis – Pipeline Review, H2 2017’, provides an overview of the Cryptosporidiosis pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Cryptosporidiosis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Cryptosporidiosis and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Cryptosporidiosis

The report reviews pipeline therapeutics for Cryptosporidiosis by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Cryptosporidiosis therapeutics and enlists all their major and minor projects

The report assesses Cryptosporidiosis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Cryptosporidiosis

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Cryptosporidiosis

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Cryptosporidiosis pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

AbbVie Inc

ioGenetics Inc

Novartis AG

Romark Laboratories LC

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 3

List of Figures 3

Introduction 4

Global Markets Direct Report Coverage 4

Cryptosporidiosis - Overview 5

Cryptosporidiosis - Therapeutics Development 6

Pipeline Overview 6

Pipeline by Companies 7

Pipeline by Universities/Institutes 8

Products under Development by Companies 9

Products under Development by Universities/Institutes 10

Cryptosporidiosis - Therapeutics Assessment 11

Assessment by Target 11

Assessment by Mechanism of Action 13

Assessment by Route of Administration 15

Assessment by Molecule Type 16

Cryptosporidiosis - Companies Involved in Therapeutics Development 18

AbbVie Inc 18

ioGenetics Inc 18

Novartis AG 19

Romark Laboratories LC 19

Cryptosporidiosis - Drug Profiles 20

DBAF-201 - Drug Profile 20

Product Description 20

Mechanism Of Action 20

R&D Progress 20

EPLAJ-1317 - Drug Profile 21

Product Description 21

Mechanism Of Action 21

R&D Progress 21

KDU-731 - Drug Profile 22

Product Description 22

Mechanism Of Action 22

R&D Progress 22

P-131 - Drug Profile 23

Product Description 23

Mechanism Of Action 23

R&D Progress 23

RM-5038 - Drug Profile 24

Product Description 24

Mechanism Of Action 24

R&D Progress 24

Small Molecules to Inhibit CDPK1 for Protozoal Infections - Drug Profile 25

Product Description 25

Mechanism Of Action 25

R&D Progress 25

Cryptosporidiosis - Dormant Projects 26

Cryptosporidiosis - Discontinued Products 27

Cryptosporidiosis - Product Development Milestones 28

Featured News & Press Releases 28

May 31, 2017: Progress reported in global fight against diarrheal disease cryptosporidiosis 28

Appendix 29

Methodology 29

Coverage 29

Secondary Research 29

Primary Research 29

Expert Panel Validation 29

Contact Us 29

Disclaimer 30

List of Tables

List of Tables

Number of Products under Development for Cryptosporidiosis, H2 2017 6

Number of Products under Development by Companies, H2 2017 7

Number of Products under Development by Universities/Institutes, H2 2017 8

Products under Development by Companies, H2 2017 9

Products under Development by Universities/Institutes, H2 2017 10

Number of Products by Stage and Target, H2 2017 12

Number of Products by Stage and Mechanism of Action, H2 2017 14

Number of Products by Stage and Route of Administration, H2 2017 15

Number of Products by Stage and Molecule Type, H2 2017 17

Cryptosporidiosis – Pipeline by AbbVie Inc, H2 2017 18

Cryptosporidiosis – Pipeline by ioGenetics Inc, H2 2017 18

Cryptosporidiosis – Pipeline by Novartis AG, H2 2017 19

Cryptosporidiosis – Pipeline by Romark Laboratories LC, H2 2017 19

Cryptosporidiosis – Dormant Projects, H2 2017 26

Cryptosporidiosis – Discontinued Products, H2 2017 27

List of Figures

List of Figures

Number of Products under Development for Cryptosporidiosis, H2 2017 6

Number of Products under Development by Universities/Institutes, H2 2017 8

Number of Products by Targets, H2 2017 11

Number of Products by Stage and Targets, H2 2017 11

Number of Products by Mechanism of Actions, H2 2017 13

Number of Products by Stage and Mechanism of Actions, H2 2017 13

Number of Products by Molecule Types, H2 2017 16

Number of Products by Stage and Molecule Types, H2 2017 16

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports